Mechanisms underlying the onset and perpetuation of chronic immune activation in individuals without overt infectious or auto-immune diseases are unclear. Cytomegalovirus is a persistent virus that induces a permanent increase of highly differentiated, IFNγ-secreting effector T cells. We hypothesized that because of this increase, CMV also induces a systemic inflammatory response. We measured acute phase proteins, cytokines and chemokines in serum from renal transplant recipients who developed a primary CMV infection and healthy CMV serum positive or negative individuals. Primary CMV infection induced a clear pro-inflammatory response that was maintained during latency. This response was characterized by increased levels of acute phase proteins like serum amyloid-A and C-reactive protein and type 1 cytokines like IL-18, IP-10 and IFNγ. This continuous activation of the immune system may play a role in the pathogenesis of chronic allograft rejection and potentially contribute to the acceleration of chronic diseases.
aBStRact
Mechanisms underlying the onset and perpetuation of chronic immune activation in individuals without overt infectious or auto-immune diseases are unclear. Cytomegalovirus is a persistent virus that induces a permanent increase of highly differentiated, IFNγ-secreting effector T cells. We hypothesized that because of this increase, CMV also induces a systemic inflammatory response. We measured acute phase proteins, cytokines and chemokines in serum from renal transplant recipients who developed a primary CMV infection and healthy CMV serum positive or negative individuals. Primary CMV infection induced a clear pro-inflammatory response that was maintained during latency. This response was characterized by increased levels of acute phase proteins like serum amyloid-A and C-reactive protein and type 1 cytokines like IL-18, IP-10 and IFNγ. This continuous activation of the immune system may play a role in the pathogenesis of chronic allograft rejection and potentially contribute to the acceleration of chronic diseases.
intRoduction
Depending on the encountered pathogen, the immune reaction shows a specific skewing towards pathogen-adapted effector responses. Conserved molecular patterns of pathogens can trigger pattern recognition receptors (PRRs) on antigen presenting cells (APC). These PRRs will trigger APCs to produce specific cytokines that control the differentiation of naive T cells. Extracellular pathogens generally induce Th2-responses which promote the differentiation of naive CD4 + T cells into helper cells that deliver T cell help to B cells. Intracellular pathogens, such as viruses, induce type 1 responses and stimulate APCs to produce IL-12 which promotes the differentiation of naive CD4 + and CD8 + T cells into IFNγ secreting effector cells 1 . Chronic diseases are often characterized by activation of the immune system and show signs of specific T cell polarization. For instance, in atherosclerosis a type 1 cytokine response predominates 2;3 , whereas colitis ulcerosa and asthma are associated with type 2 cytokine responses 4;5 . Factors that permanently change the differentiation of the immune system, may contribute to disease progression.
Although viral infections typically induce type 1 responses, previous studies have reported contradictory results regarding the polarization of the immune response against Cytomegalovirus (CMV). Some studies showed a type 2 cytokine profile [6] [7] [8] [9] , while others revealed a predominant type 1 cytokine response [10] [11] [12] . We have shown previously that circulating virus-specific T cells synthesize type 1 cytokines IFNγ and TNFα, but not the type 2 cytokine IL-4 during primary CMV infection 13 . During CMV latency a pool of highly differentiated CMV-specific CD4 + and CD8 + T cells is maintained after resolution of the primary infection, in contrast to other persistent herpesviruses.
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These CMV-specific T cells contain cytotoxic molecules such as granzyme-B and can produce high amounts of IFNγ and TNFα [14] [15] [16] . We here studied whether the induction and maintenance of IFNγ secreting T cells is also reflected by sustained changes in serum cytokine levels. We show that CMV infection induces a systemic inflammatory response with a clear type 1 cytokine signature in serum that parallels the changes observed in the cellular compartment during both primary infection and latency.
methodS

Patients and healthy individuals
For the measurements of cytokine levels we used two cohorts. One consisted of 36 renal transplant recipients and the other of 74 healthy non-immunosuppressed individuals. The renal transplant recipients all received their transplant during the years 1999-2005, and were CMV seronegative before transplantation. Eighteen recipients received a kidney from a CMV seronegative donor and 18 from a CMV seropositive donor. Patients who received a kidney from a CMV seropositive donor developed a primary CMV infection defined as a transient presence of CMV-DNA in peripheral blood and the formation of IgG antibodies specific for CMV. The viral peak occurred at a mean of 2.5±1.2 months, ranging from 1.2 to 6.0 months post transplantation. The viremia ended at a maximum of 7.2 months post transplantation. One patient developed a short second episode of detectable viremia with a duration of 2 weeks, ending 2.9 months after transplantation The peak viral load ranged from 27x10 3 to >1x10 6 copies/ml with a mean of 41x10 4 ±38x10 4 copies/ml. At the time period of our study, none of the patients at risk for primary CMV infection received preemptive treatment or prophylactic. Ten of these patients developed clinical symptoms including fever, flu-like syndrome and gastrointestinal complaints and received antiviral treatment consisting of oral ganciclovir (n=3) or oral valganciclovir (n=7). Table 1 shows that both patient groups had comparable characteristics. From the recipients who received a CMV positive donor organ, blood samples were collected before transplantation (preTx), 1 week after transplantation (1wk after Tx), at the peak of CMV infection (peak CMV) and at 1 year after Tx (1yr after Tx). Blood samples of patients who remained CMV seronegative, were collected at comparable time points relative to time of transplantation. The cohort of healthy individuals consisted of 37 CMV seronegative and 37 age-and sex-matched seropositive individuals. The study was approved by the Medical Ethics Committee of the Academic Medical Center Amsterdam. All individuals gave informed consent.
isolation of peripheral blood mononuclear cells (PBmc) and serum
To obtain peripheral blood mononuclear cells, blood was diluted twice in HBSS (Cambrex Corporation, New Jersey, USA) 0.025 M Tris pH 7.0; layered on lymphoprep 148 (Lucron Bioproducts, De Pinte, Belgium; 1.077 g/ml) and centrifuged (400g for 20 minutes at 25ºC) without brake. The white blood cell ring was isolated and cells were cryopreserved until day of analysis. Serum samples were obtained after centrifugation of blood samples at 1550g for 10 minutes. The serum was subsequently aliquoted and stored at -20 oC.
cmV-PcR and cmV antibody levels
Quantitative PCR was performed in EDTA whole blood samples as described before 17 . In patients developing a primary CMV infection, the presence of CMV-DNA was monitored weekly until no CMV-DNA could be detected anymore. To determine CMV serostatus, anti-CMV IgM and IgG antibody levels were measured in serum using the AxSYM microparticle enzyme immunoassay (Abbott Laboratories, Abbott Park, IL) according to the manufacturer's instructions. Measurements were calibrated relative to a standard serum.
facS analysis of cmV specific cd4 + and cd8 + t cell CMV-specific CD4 + and CD8 + T cell frequencies were determined as described earlier [18] . The frequency of CMV specific CD4 + T cells was determined by incubating PBMCs . CMV specific CD8 + T cells frequency was determined by stimulation of PBMCs with either HLA-A2 or B7-binding CMV pp65-derived peptide at a final concentration of 1.25 μg/ml (all purchased from IHB-LUMC peptide synthesis library facility; Department of Immunohaematology and Blood Bank, LUMC, Leiden, the Netherlands). Five hours prior to analysis brefeldin-A was added to the culture with a final concentration of 10 μg/ml. After culture, cells were stained with FITC conjugated IFNγ, PE conjugated CD69 mAb and APC conjugated CD4 or CD8 mAb (Becton Dickinson). Flow cytometric analysis was done using FacsCalibur and samples were analyzed using FlowJo version 8.
multiplex assay for cytokine measurement
Serum was analyzed using the Human Cytokine Luminex 30-plex and Human-4plex purchased from Bioscource (Invitrogen) and Human-duoplex purchased from Bioplex (Biorad). All reagents were provided with the Bioscource (Invitrogen) kit and the assay was performed according to the provided protocol.
eliSa
Serum levels of IL-12, IL-18, IFNγ, IP-10 and IL-13 were measured by enzyme-linked immunosorbent assay (ELISA). ELISA for the measurement of IL-12 (sensitivity: 0.686 pg/ml) and IL-13 (0.5 pg/ml) were purchased from Sanquin (Amsterdam, The Netherlands). The IP-10 (6.25 pg/ml), and high sensitive IFNγ (0.69 pg/ml) ELISA were purchased from Diaclone (Besancon, France). All serum samples were thawed once and at least 80 samples were measured at the same time.
c-reactive protein (cRP) measurement
Serum CRP levels were measured within the clinical diagnostics facility of the Academic Medical Center, Amsterdam using commercial immune turbidimetric highsensitivity CRP methods adapted to the P800 autoanalyzer (Roche Diagnostics, Basel, Switzerland). This assay has a sensitivity of 0.6 mg/L
Statistical analysis
Cytokine levels below detection level were set at lowest measurable value. For comparison of cytokine levels between different time points measured by Luminex, we used the non-parametric Kruskal-Wallis test because of the small number of patients (n=9). For the comparison of the ELISA measurements we used one-way ANOVA test due to the increased group size (n=18) and normally distributed data. The ELISA data were analyzed by a subsequent post-hoc test, to compare the means of each time point with the means obtained at preTx. Correlations were analyzed by Spearman's rank correlation test. For the remaining statistical analyses we used unpaired Student's t-test, Mann-Whitney U test or χ 2 test, as indicated. A p-value of less then 0.05 was considered significant. Statistics were calculated using GraphPad Prism 5 for Window, version 5.01.
ReSultS type 1 cytokine levels are increased during primary cmV infection after renal transplantation
We longitudinally collected sera from 18 renal transplant recipients who developed a primary CMV infection and randomly selected 9 patients for initial screening of cytokine levels using Luminex The Luminex screening revealed that multiple type 1 cytokine and chemokine levels changed during primary infection (IL-18, IP-10, MIG, MCP-1), whereas none of the type 2 cytokine levels changed (IL-4, IL-5, IL-13). The only exception to this was an increase in the type 2 chemokine Eotaxin late after transplantation ( Table 2) . No change was seen in the levels of the bioactive form of IL-12. However, a decrease in IL-12p40 levels was observed already 1 week after transplantation.
We also measured other factors, some of which fluctuated as a result of the transplantation or CMV infection (Suppl. Table 1 -upper panel). During the peak of infection, we found increased serum levels of IL-10, which is an immunoregulatory cytokine produced by Th1, Th2 and Treg cells [18] [19] [20] . Furthermore, we noted a decrease in pro-inflammatory cytokine levels (IL-8, IL-1Rα) after transplantation. In contrast to the decrease in pro-inflammatory mediators, CMV infection also induced an increase in acute phase protein serum amyloid A (SAA) accompanied by an increase in soluble IL-2Rα, pointing to immune activation during viral infection. Finally, levels of the soluble form of adhesion molecules VCAM-1 and ICAM-1 changed during CMV infection, indicating the activation of endothelial cells. None of the measured growth factors changed during the course of CMV infection (Suppl. Table 1 -lower panel) .
To confirm the predominant type 1 cytokine response during CMV infection we extended the group of patients with primary CMV infection to a total of 18 and measured a selection of type 1 and type 2 cytokines and chemokines by ELISA. To dissect the influence of CMV infection on serum cytokine levels from that of immunosuppression and presence of an allograft, we also included a group of patients remaining CMV seronegative. Although we measured no changes in IL12p70 and IFNγ levels using Luminex, we did include these cytokines due to their central role in type 1 immune responses. In line with the Luminex measurements, serum IL-18 was markedly increased during the peak of CMV infection (p< 0.0001, Fig. 1A , left panel), but decreased in patients remaining CMV seronegative (data not shown). No significant differences were measured in IL-12p70 levels during primary CMV infection (Fig. 1A, right panel) . In contrast to measurements with Luminex, using the high sensitive IFNγ ELISA we found that IFNγ levels were increased during the peak of CMV infection (p< 0.0001, Fig. 1B, left panel) . No significant changes in cytokine levels were observed in the CMV seronegative patients (data not shown). IP-10 was highly increased during the peak of infection (p< 0.0001) and remained elevated during the latency phase, one year after transplantation (p= 0.01, Fig. 1B , right panel), contrasting to unaltered IP-10 levels in transplant recipients remaining CMV seronegative (data not shown). Finally, levels of the prototypic type 2 cytokine IL-13 did not change during the course of a primary CMV infection in either patient group (Fig. 1C and data not shown) .
To analyze whether CMV also induces chronic non-specific inflammation we measured levels of acute phase protein, CRP. Figure 1D shows that also CRP levels were increased during the peak of CMV infection compared to the other time points (p< 0.05). CRP levels of patients remaining CMV seronegative stayed unaltered (data not shown). Interestingly another acute phase protein measured by Luminex, SAA, also showed an increase during the peak of primary CMV infection (Table 2) . Based on these results, we concluded that primary CMV infection induces a systemic inflammatory response characterized by a type 1 cytokine signature.
during primary cmV infection, cellular responses and serum ifnγ levels follow cmV-dna levels
We have previously shown that CMV specific CD4 + and CD8 + T cell populations expand and subsequently contract during primary infection 21 . We analyzed the percentage of CMV specific CD4 + and CD8 + T cells at four different time points after primary CMV infection ( Fig. 2A and C) . Parallel to this, we measured IFNγ levels in serum together with CMV-DNA copy number in serum at weekly intervals during primary CMV infection up to the latency phase of infection ( Fig. 2B and 2D ). IFNγ serum levels closely parallel the CMV-DNA load in blood and the cellular responses of CMV specific CD4 + and CD8 + T cells, showing a quick rise and fall. These data together indicate that CMV induces not only changes in the T cell compartment but also in type 1 cytokine levels in serum.
type 1 cytokines remain elevated during latent cmV infection after renal transplantation
A year after the peak of primary CMV infection, all infected patients had undetectable CMV-DNA in blood and produced CMV-specific IgG antibodies. We compared the levels of type 1 cytokines in patients one year after the peak of primary CMV infection to CMV seronegative at comparable time point after transplantation. None of the patients showed clinical signs of acute rejection or active infection during the one year follow up after transplantation. Before-and one week after transplantation, cytokine levels in both groups were similar (data not shown). In patients with latent CMV infection, serum levels of IL-18 and IL-12p70 were higher as compared to the 
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CMV seronegative control patients (p= 0.004, respectively p= 0.002, Fig. 3A) . IL-18 levels increased in the patients with primary CMV infection and IL-12p70-levels decreased in the non-infected patients. There was also an increase in IFNγ (p= 0.001) and IP-10 (p= 0.001) levels during latency (Fig. 3B) . No difference in IL-13 levels was observed between both patient groups (Fig. 3C) . Finally, CRP levels in patients with CMV remained elevated during latency (Fig. 3D) . From these data we conclude that in renal transplant recipients, a systemic inflammatory response is sustained during CMV latency, as reflected by an increase in type 1 cytokines but no change in type 2 cytokines. 
latent cmV infection in healthy individuals induces a sustained systemic inflammatory-response with a type 1 cytokine signature
To study whether the changes in serum cytokine were also present during latent CMV infection in non-immunosuppressed individuals, we measured IP-10, IFNγ and CRP levels in serum from 37 CMV seropositive and 37 age-and sex-matched CMV seronegative healthy individuals. Although we did not observe any difference between both groups with respect to IP-10 levels (Fig. 4A, left panel) , IFNγ serum levels in CMV seropositive individuals were higher compared to CMV seronegative individuals (p= 0.009, Fig. 4A right panel) . In addition, in line with the observations during latent infection in renal transplant recipients, CRP levels were increased in CMV seropositive individuals (p= 0.006, Fig. 4B ). For the individuals with detectable IFNγ levels, the amount of IFNγ correlated with CRP levels (r= 0.55, p= 0.01, Fig.  4C ). These data indicate that also in healthy individuals CMV infection induces a sustained inflammatory response with an increase in serum levels of both CRP and the prototypic type 1 cytokine IFNγ. 
diScuSSion
Here, we show that human primary CMV infection induces systemic inflammation characterized by elevated CRP and SSA levels, and a predominant type 1 cytokine response. Serum levels of the prototypic type 1 cytokines IL-18 and IFNγ were elevated during primary CMV infection and remained so during latency, where also IL-12 levels appeared to be increased. IL-12 and IL-18 are known to regulate the development of naïve T cells through the induction of transcription factors such as T-bet. This transcription factor is required for activation, differentiation and maturation of IFNγ secreting CD4 + Th1 and cytotoxic CD8 + T cells 22;23 . Indeed, we recently showed increased expression of T-bet in CMV specific CD8 + T cells from primary infection into latency 24 . In agreement with previous studies, we found increased serum IL-10 levels during CMV-infection [6] [7] [8] [9] . This is an important cytokine in the inhibition of the immune response. The cellular source of this human IL-10 (Luminex does not detect viral IL-10) is not known. It is known that effector T cells can produce IL-10 25 ; and in view of the type 1 polarized immune cytokine response, we suppose that during primary CMV infection Th1 cells could have produced these increased amounts of IL-10. However, analysis of intra-cellular cytokine production failed to reveal IL-10 production by CMV-specific cells (data not shown). This may indicate that IL-10 was also produced by cells from the innate immune system such as macrophages or monocytes 26 . In contrast to the study by Sadeghi et al, we found clear increases in serum IFNγ levels during primary CMV infection, which remained elevated during latency 9 . A possible explanation for the discrepancy in results is a difference in sensitivity of the ELISAassays. Initially, using Luminex which has a sensitivity 5 pg/ml we failed to detect a change in serum IFNγ levels. However, using a high sensitive IFNγ ELISA with a sensitivity of <0.69 pg/ml we did find differences. In support of our findings, we could detect marked intracellular expression of IFNγ in CMV specific T cells that matched the increased serum levels measured at the same time points.
Cytokine levels can be influenced by pre-transplantation dialysis; initiation of immunosuppressive drug treatment and postoperative complications like delayed graft function, rejection and infection 27;28 . We eliminated the influence of these factors by comparing serum samples taken before and one week after transplantation, and by comparing cytokine levels in patients developing primary CMV infection with those from patients that remained CMV seronegative. In addition, we excluded patients who developed acute rejection or other overt infections. We conclude that CMV causes chronic systemic immune activation. The lack of detectable CMV-DNA in serum during latency with the presence of highly differentiated CMV specific cells that depend on antigen for survival indicates that CMV induces local, low-grade infection, possibly occurring in salivary glands and kidney.
This in turn will activate the CMV specific cells to produce IFNγ in high amounts, which can be measured systemically. However, some CMV seropositive transplant recipients and healthy individuals did not show signs of immune activation, suggesting that additional factors are involved. On the other hand, some of the CMV seronegative individuals showed increased serum cytokine levels which may reflect transient acute phase responses and indicate that CMV is not absolutely required for the development of chronic immune activation.
Although the issue remains controversial, CMV infection has been implicated in the development of acute and chronic transplant rejection 29;30 . The continuously elevated serum IFNγ levels as demonstrated in the present study, may contribute to augmented allo-immune responses by enhancing the expansion and function of alloreactive T cells. Moreover, the chronically increased serum IFNγ levels during latency can lead to a higher expression of HLA molecules on graft-cells, increasing the risk of recognition by allo-antigen specific T cells which leads to allograft-rejection. The recent demonstration of primary involvement of IFNγ, T-bet and granzyme B in the pathogenesis of transplant glomerulopathy, being a major risk factor for chronic rejection, makes CMV infection by its induction of chronic type 1 cytokine polarization a highly suspect candidate for playing a pathogenetic role in chronic rejection 31 . In addition, we show that during primary CMV infection not only type 1 cytokines but also serum levels of soluble ICAM-1, VCAM-1 and IP-10 are elevated, suggestive for endothelial cell-activation which will result in increased expression of HLA molecules on these cells.
CMV infection appeared to induce a chronic pro-inflammatory state not only in immunosuppressed patients, but also in healthy individuals. We found a correlation between serum CRP and IFNγ levels during latent CMV infection in healthy, non-immunosuppressed individuals, pointing to the involvement of both acute phase response proteins and type 1 cytokines in generating a pro-inflammatory state after CMV-infection. There are chronic diseases, such as atherosclerosis or immunosenescence, which are associated with chronic immune activation. The CMVinduced pro-inflammatory state could play a role in the formation or progression of these diseases. Indeed, CMV infection, and in particular the way the immune system deals with this persisting pathogen, may be a major driving force behind the phenomenon of immunosenescence. This age-associated decrease in immune function is thought to be an important cause of increased morbidity and mortality due to infections in older people 32;33 . Next, CMV infection is associated with progression of atherosclerotic disease, an inflammatory state in which type 1 cytokines play an important role 2;34 . Increased serum IFNγ levels are known to promote macrophage and endothelial activation, resulting in increased expression of chemokines and adhesion molecules finally leading to reduced plaque stability 35;36 . By the induction of a pool of highly differentiated cytotoxic cells capable of migrating to activated endothelium, 159 where they produce chemotactic cytokines, CMV could provide a positive feedback loop for the attraction and activation of immune effector cells to the vascular wall.
In conclusion, by promoting a type 1 cytokine polarization of the immune response, CMV probably contributes to the pathogenesis of chronic allograft rejection. The systemic immune activation as found in healthy individuals may contribute to the acceleration of chronic diseases such as immunosenescence and atherosclerosis but confirmation by a prospective study using a larger patient cohort in which chronic disease progression is correlated to changes in systemic immune activation is warranted. 
